Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB) -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (487)	1/1/1998 11:28:00 AM
From: Brander	Read Replies (1) \| Respond to of 834

Bill, other posts you made were stronger, but, nevertheless, we will go with your new position, which is: "I said that TXB set up the tests improperly and placed a positive "spin" on statistically insignificant positive responses." Again, these are pretty serious accusations, and still without any supporting evidence, whatsoever. Where are your supporting facts? Can you give us any specific points or examples as to how they set up their tests improplerly? And, can you please explain, statistically, how and why the results are insignificant? The research studies I have read on Novastan seem proceedurally intact and sound, and the results are statistically significnt. If what you say is true, some very renowned invstigators would have to be involved, and they would not risk their scientific careers, let alone compromise their ethics, to publish misleading research papers. Also, the FDA would never have allowed Novastan to get this far....only one more step until acceptance and marketing. Also, TXB would be heavily fined and probably delisted, and they are a lot more intelligent than that. The Board of Directors has some very ethical, intelligent, and wise members who would not allow what you accuse TXB of doing. Your accusations about these clinical trials are far fetched and without any evidence at all. In fact, the available evidence strongly supports the assumption that the clinical trials for Novastan were performed in accordance with scientific standards, the results were statisticaly significant and they support a therapeuticly effective medication. Brad